According to a new study, 50% of men in the U.S. with BRCA1/2 and metastatic castration-resistant prostate cancer receive PARP inhibitor treatment.1 This study also found that PARP inhibitor treatment differed by insurance coverage, with PARP inhibitors among commercially insured LESS LIKELY than those covered by government-issued insurance.
Similarly, a U.S.-based study of adults with HER2-negative breast cancer showed that from 2018 onwards (i.e., the year both Olaparib and Talazoparib were approved for use in metastatic breast cancer in BRCA1/2-positive patients), less than 50% of BRCA1/2 carriers received PARP inhibitors.2 These findings suggest that even though we have life-prolonging treatment for these individuals (PARP inhibitors), many are not receiving it. It remains important to improve awareness regarding data to support using PARP inhibitors and ensure access to these agents.
1Ostrowski, et al. JAMA Netw Open. 2025;8(10):e2534968. PMID: 41037269.
Article available at: https://pubmed.ncbi.nlm.nih.gov/41037269/
Social media post available at: https://www.facebook.com/share/p/1G9tHiA2Gp/
2Yadav S, et al. JCO Precis Oncol. 2025:e2400814. PMID: 40669020.
Article available at: https://pubmed.ncbi.nlm.nih.gov/40669020/